Portrait of Dr. Alexander Vladimir Kornienko

Dr. Alexander Vladimir Kornienko

  • Professor at Chemistry and Biochemistry, College of Science & Engineering

Grants

2026

  • Kornienko, Alexander Vladimir (Principal). Fungal Sphaeropsidin A for Refractory Cancer, Texas State Office of Innovation, Texas State University, $30000. (Submitted: November 2025, Funded: January 2026 - December 2027). Grant.

2025

  • Kornienko, Alexander Vladimir (Principal). Sphaeropsidin derivatives to combat cancers, Formosa Plastics, Private / Foundation / Corporate, $17000. (Funded: September 2025 - August 2027). Grant.
  • Kornienko, Alexander Vladimir (Co-Principal), Romo, Daniel (Principal). Pharmacophore-Directed Retrosynthesis Applied to Bioactive Natural Products Informing Mechanism of Action Studies, NIH, Federal, $2250000. (Submitted: January 2024, Funded: January 2025 - December 2029). Grant.

2021

  • Kornienko, Alexander Vladimir (Principal). Denise M. Trauth Endowed Presidential Research Professorship, Texas State University, Texas State University, $90000. (Submitted: 2021, Funded: 2021 - 2024). Grant.

2020

  • Kornienko, Alexander Vladimir (Co-Principal), Romo, Daniel (Principal). Pharmacophore-Directed Retrosynthesis Applied to Bioactive Natural Products Informing Mechanism of Action Studies, National Institutes of Health, Federal, $1422000. (Submitted: February 5, 2019, Funded: January 1, 2020 - December 31, 2024). Grant.

2019

  • Kornienko, Alexander Vladimir (Principal), La Clair, James (Co-Principal). Tandem Discovery of Drug Leads and Targets via Paal-Knorr reaction, National Institutes of Health, Federal, $374000. (Funded: September 1, 2019 - August 31, 2021). Grant.
  • Kornienko, Alexander Vladimir (Principal), Sun, Dandan (Co-Principal). Acid-Sensitive Glioblastoma Prodrugs Derived from Ophiobolin A, National Institutes of Health, Federal, $461764. (Funded: February 1, 2019 - January 31, 2023). Grant.

2014

  • Kornienko, Alexander Vladimir (Principal), Romo, Daniel (Co-Principal), Rohatgi, Rajat (Co-Principal). Mode of Action of the Amaryllidaceae Alkaloid Lycorine-Promising Anticancer Agent, NIH/NCI/AREA – CA186046-01A1, $475518. (Funded: July 15, 2014 - June 30, 2017). Grant.